Navigation Links
Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
Date:4/2/2011

r in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. The rise in incidence of CDI, along with high rates of both treatment failures and recurrences with current therapies have resulted in greater awareness and concern about CDI among medical professionals and public health officials. You may learn more about CDI at www.cdiinfo.org, a website of Optimer.

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Co
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. (NYSE ... drug candidates targeting specific pathogens that cause serious infections ... unusual market activity in the Company,s stock, the NYSE ... with its usual practice. The Company stated that its ... About Synthetic Biologics, Inc. Synthetic ...
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... YORK , July 29, 2014  Longtime industry ... Caremark Rx, Drew Crawford today announced the ... the leading independent media source dedicated to delivering fair, ... on the pharmacy benefit management (PBM) industry .  ... of, and context behind, industry news.   The outlet will ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2
(Date:7/30/2014)... Computer Resources of America, Inc. (CRA), an ... City, has been awarded the contract to rewire the ... large global bank. The bank is a global leader ... of CRA said, “Being awarded this contract with our ... what has already been a successful and deep relationship. ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review ... for men who want to discover how to increase their ... within a few months. Inside this book, learners will discover ... and avoid the aches and pains. , Vkool reveals in ... learners the reason why stretching and warming up is so ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... VisitandCare.com today announced that several ... the company’s exclusive network to help couples struggling with ... — as top fertility clinics in Spain, Switzerland, Greece, ... and successful IVF treatments. , The exclusive selection of ... by professionals at VisitandCare.com. The goal is to connect ...
(Date:7/29/2014)... 2014 Phytceramides are a natural anti-aging tool for ... new book. , Today is the last day to nab a ... Best . The book is also sold in hard copy. , ... that Phytoceramides were so new and very unknown in ... book now," says Kathy Heshelow, founder of Sublime Beauty®. "It is ...
Breaking Medicine News(10 mins):Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3
... Services, Treatment and Prevention Available--MINNEAPOLIS, April 29 ... health care centers in the United States, is ... flu (H1N1) and provide rapid testing services, treatment ... medically appropriate. MinuteClinic is coordinating with local ...
... 29 Grupo Aeroportuario del Sureste, S.A.B. de C.V. ... first privatized airport group in Mexico and operator of Cancun ... today that on April 26, 2009 the Mexican Secretary of ... in Mexico. On April 28, 2009 the World Health Organization ...
... BOTHELL, Wash., April 29 SCOLR Pharma, Inc. (NYSE Alternext ... financial results on Friday, May 1, 2009, at 8:30 a.m. ... Pharma, will host the conference call at 11:30 a.m. Eastern, ... other interested parties may participate in the conference call by ...
... Survey finds many cities have dangerously high levels of pollution ... of the nation,s population, 186.1 million people to be exact, ... air pollution, new research shows. , "Six out of ten ... the emergency room, to shape how kids, lungs develop and ...
... 2009 Relationships are difficult and most of us probably ... when discussing stressful issues, like home finances, is an impossible ... take the "edge" off these discussions? The biology of ... research on social cognition conducted in animals is now informing ...
... Michigan physicians are the first in the nation ... through a new partnership announced today by the American ... with Compuware,s Covisint subsidiary. This partnership builds on ... the AMA announced its agreement with Covisint to develop ...
Cached Medicine News:Health News:MinuteClinic is Educating Consumers About Swine Flu 2Health News:MinuteClinic is Educating Consumers About Swine Flu 3Health News:SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern 2Health News:More Than Half of Americans Living with Dirty Air 2Health News:More Than Half of Americans Living with Dirty Air 3Health News:Oxytocin: Love potion #1? 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... qualitative differential detection of ... and an antigen that is ... of malaria:plasmodium falciparum (P.f), plasmodium ... and Plasmodium malariae (P.m) in ...
Medicine Products: